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Implantable defibrillators reduce the risk of sudden death in 
patients with malignant ventricular arrhythmias, but significant 
restriction in quality of life can occur as a result offrequent device 
activation. To determine if a device that provides both antitachy-
cardia pacing and shock therapy can safely reduce the frequency 
of shocks after implantation, 46 consecutive patients undergoing 
initial implantation of a defibrillator were studied. In all patients, 
the implanted device provided antitachycardia pacing and shock 
therapy. Detected tachycardia characteristics and the results of 
therapy were stored in the device's memory. 
There were 42 men and 4 women, aged 26 to 71 years (mean 
58.7 ± 13.5). Left ventricular ejection fraction ranged from 13% 
to 67% (mean 32.2 ± 13.4%) and 31 patients had experienced one 
or more episodes of cardiac arrest. Induced arrhythmias included 
sustained monomorphic ventricular tachycardia in 38 patients, 
nonsustained polymorphic ventricular tachycardia in 2 and ven-
tricular fibrillation in 4. 
Over a total follow-up period of 255 patient-months (range 1 to 
Treatment of ventricular tachycardia with antitachycardia 
pacing is limited by the unpredictable occurrence of pacing-
induced and spontaneous ventricular fibrillation 0-5). As a 
result, patients with refractory ventricular tachycardia have 
been treated with an implantable defibrillator that is commit-
ted to deliver a high energy shock for any detected tachyar-
rhythmia (6-8). Although implantable defibrillators appear 
to reduce the risk of sudden death, quality of life may be 
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13, mean 6.1), 25 patients experienced spontaneous arrhythmic 
events. In 22 patients, 909 episodes of tachycardia were treated by 
antitachycardia pacing, which was successful on 840 occasions 
(92.4%). Acceleration of ventricular tachycardia by pacing ther-
apy was estimated to have occurred 39 times. Syncope occurred 
once during pacing-induced acceleration of ventricular tachycar-
dia. Forty-four episodes of tachycardia in seven patients were 
treated directly by shocks because of short tachycardia cycle 
length; 88% of all detected tachycardias were treated without the 
need for shocks. Four patients died from cardiorespiratory failure 
and one patient died suddenly without any detected tachyarrhyth-
mia. 
These initial results demonstrate that a device that provides 
graded therapy with antitachycardia pacing for ventricular ar-
rhythmias reduces the need for high energy shocks and rarely 
results in detrimental delays in the treatment of ventricular 
tachycardia. 
(J Am Coli CardioI1991;18:145-51) 
impaired by frequent shocks and the continued need for 
antiarrhythmic medication (9,10). Devices that combine an-
titachycardia pacing and defibrillation have recently become 
available (6,11,12). The use of antitachycardia pacing may 
reduce the frequency of defibrillation shocks but has the 
possible disadvantage of delaying effective treatment during 
hemodynamically unstable tachycardia. 
The purpose of the present study was to determine if a 
device providing both antitachycardia pacing and shock 
therapy could substantially reduce the frequency of shocks 
without detrimental delays in the treatment of hemodynam-
ically unstable tachycardia. 
Methods 
Description of the device (Fig. 1). A description of a 
prototype of this device has been published elsewhere (0). 
The devices implanted (Medtronic models 7216 and 7217) 
have the ability to perform defibrillation, cardioversion, 
antitachycardia pacing and ventricular-inhibited (VVI) 
bradycardia pacing (Fig. 1). Tachycardia detection was 
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UNSUCCESSFUL ACCELERATION * 
TERMINATION TERMINATION 
based on heart rate criteria, with facilities for additional 
criteria based on tachycardia onset and cycle length stability 
characteristics. In the present series, only heart rate criteria 
were used. Detected tachycardias were categorized by the 
device as either high rate or low rate on the basis of 
tachycardia cycle length criteria individualized for each 
patient. Low rate tachycardia therapy was intended for 
stable ventricular tachycardia. Up to four low rate tachycar-
dia therapies could be programmed, with each therapy 
consisting of either sequences of antitachycardia pacing 
(adaptive decremental pacing or adaptive burst pacing) or a 
single shock. High rate tachycardia therapy was intended for 
hemodynamically unstable ventricular tachycardia or ven-
tricular fibrillation and consisted of up to four high energy 
countershocks. 
Antitachycardia pacing (Fig. 2 and 3). The cycle length of 
antitachycardia pacing was programmed to commence at 
80% to 97% of the detected tachycardia cycle length. Each 
therapy consisted of 1 to 15 pacing sequences of either burst 
or decremental pacing. Burst pacing consisted of a series of 
1 to 15 regular ventricular impulses. If unsuccessful, the 
pulse interval for the next burst sequence was decremented 
by a programmable value until either reversion of the tachy-
cardia or until the programmed number of burst pacing 
sequences was delivered. Decremental pacing consisted of a 
series of 1 to 15 ventricular impulses, with each paced 
ventricular interval decrementing from the preceding inter-
val by a programmable value. If unsuccessful, the number of 
pulses in each additional sequence was increased by 1 (for a 
maximum of 29 impulses if programmed for 15 impulses in 
the initial sequence) (Fig. 2 and 3). Decremental pacing was 
chosen as initial antitachycardia pacing therapy for evalua-
tion in all patients. Burst pacing was not routinely evaluated 
unless decremental pacing was unsuccessful. 
Synchronized countershocks could be delivered at ener-
gies ranging from 0.2 to 34 J over single- or dual-current 
pathways. If antitachycardia pacing or low energy shocks 
Figure 1. Simplified flow diagram of tachycardia detec-
tion and treatment by the implantable pacemaker-
cardioverter-defibrillator. Each tachycardia was catego-
rized by cycle length criteria as either "low rate 
UNSUCCESSFUL tachycardia" (LRT) or "high rate tachycardia" (HRT). 
Low rate tachycardia could be treated by either burst or 
decremental pacing or shock therapy, whereas high rate 
tachycardia could be treated only by shock therapy. See 
text for details. *If acceleration of tachycardia was not 
sufficient to result in detection of high rate tachycardia, 
the next therapy for low rate tachycardia was delivered. 
Figure 2. Termination of spontaneous ventricular tachycardia by 
autodecremental antitachycardia pacing recorded by ambulatory 
EeG monitoring during follow-up study. Nine seconds after the 
onset of spontaneous ventricular tachycardia (cycle length 320 ms), 
antitachycardia pacing begins (MARKER). Decrementai pacing was 
programmed to start with five pulses commencing at 97% of the 
detected tachycardia cycle length (in this instance the first coupling 
interval was thus 310 ms). Each pulse in the train decremented by 
10 ms. When a sequence was unsuccessful, one additional paced 
impulse was added to the subsequent sequence. The third sequence 
with seven pulses (last coupling interval 250 ms) terminates the 
tachycardia. These strips are continuous. 
MARKER 
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Figure 3. Acceleration of induced ventricular tachycardia by anti-
tachycardia pacing and subsequent defibrillation by the device. 
Ventricular tachycardia was induced by programmed stimulation 
from the device at predischarge electrophysiologic testing. Upper 
panel, Decremental pacing therapy accelerates ventricular tachycar-
dia from a cycle length of 305 to 280 ms. The second trial of 
decremental pacing therapy further accelerates ventricular tachy-
cardia. Lower panel, "High rate tachycardia" detection criteria are 
met after acceleration of tachycardia to a cycle length of 235 ms. An 
18 J countershock successfully converts ventricular tachycardia to 
sinus rhythm. Four surface leads (I, a VF, V I' V 6) and the defibril-
lator electrogram interpretation channel (MC) are shown. In the 
latter channel, each detected beat of low rate tachycardia, is 
indicated by a full length double impulse and each beat of high rate 
tachycardia by a half-size double impulse. 
accelerated ventricular tachycardia so that high rate tachy-
cardia was detected, the device went on to deliver the 
programmed high rate tachycardia shocks. 
Model 7216 (36 patients) and 7217 (10 patients) were 
similar except for the leads used for sensing and pacing. 
Model 7216 used a modified bipolar lead (an epicardial 
screw-in electrode as the cathode and a defibrillation patch 
as the anode), whereas model 7217 used a true bipolar lead 
system with two epicardial screw-in electrodes or, in the 
case of trans venous leads, a bipolar screw-in electrode in the 
right ventricular cavity. Countershocks had a monophasic 
truncated exponential wave form and were delivered across 
two or three epicardial mesh electrodes or transvenous 
catheter electrodes. 
All therapy delivered by the device was stored in memory 
and was retrievable by telemetry. The last 20 RR intervals of 
the last arrhythmia satisfying detection criteria along with 
the first 10 RR intervals after the last therapy delivered were 
recorded by the device. The device deemed a therapy 
successful if tachycardia (as defined by the heart rate crite-
ria) was no longer present after therapy. 
Patient selection. Patients with ventricular tachycardia or 
ventricular fibrillation not secondary to acute myocardial 
Table 1. Clinical Features and Electrophysiologic Findings in the 
46 Patients 
Age (yr) 
Male gender 
Cardiac diagnosis 
Coronary artery disease 
Dilated cardiomyopathy 
Valvular heart disease 
ARVD 
None 
Cardiac tumor 
Ejection fraction (%) 
Presenting arrhythmia 
VT 
VF 
Sudden cardiac death (no documented 
arrhythmia) 
Previous cardiac arrestt 
Inducible ventricular arrhythmia at EP 
Monomorphic VT 
Ventricular fibrillation only 
Nonsustained polymorphic VT 
None 
No. of Patients 
58.7 ± 13.5' 
42 
37 
4 
2 
32.2 ± 13.4' 
35 
9 
2 
31 
38 
4 
2 
2 
'Mean ± SD. tDefined as sudden loss of consciousness requiring cardio-
version. ARVD = arrhythmogenic right ventricular dysplasia; EP = electro-
physiologic study; VF = ventricular fibrillation; VT = ventricular tachycar-
dia. 
infarction, myocardial ischemia, electrolyte imbalance or 
any other reversible cause were candidates for device im-
plantation. Patients resuscitated from sudden cardiac death 
without documented cardiac arrhythmias were also consid-
ered for device implantation. Eligibility was not contingent 
on antiarrhythmic drug failure for patients resuscitated from 
cardiac arrest. Those with hemodynamically well tolerated 
ventricular tachycardia as their only tachyarrhythmia had to 
demonstrate antiarrhythmic drug failure before device im-
plantation. Forty-six consecutive patients undergoing initial 
defibrillator implantation at the two centers (University 
Hospital, Ontario and Foothills Hospital, Calgary) had this 
device implanted and are included in this report (Table 1). 
The study was approved by the Review Board for Human 
Research at the University of Western Ontario on March 3, 
1989 and at the University of Alberta on January 19, 1989. 
Written informed consent was obtained before implantation 
of the device. 
Implantation and postoperative testing. When epicardial 
leads were used, the device was implanted by either median 
sternotomy or a sub xiphoid approach. Two or three epicar-
dial patches and two pace-sense electrodes were positioned 
on the heart as previously described (11). Transvenous leads 
were used in nine patients and included a right ventricular 
electrode, a superior vena cava electrode and either a 
coronary sinus electrode (five patients) or a subcutaneous 
patch in the left axilla (four patients). The device was 
implanted after three successful defibrillations at stored 
energies of :518 J. 
148 LEITCH ET AL. 
COMBINED ANTlTACHYCARDlA PACING AND SHOCK THERAPY 
JACC Vol. 18, No.1 
July 1991: 145-51 
Antitachycardia pacing therapy was evaluated 7 to 10 
days postoperatively. Noninvasive ventricular programmed 
stimulation studies were peIformed with the device deliver-
ing up to three extrastimuli at two or more drive cycle 
lengths. The ability of antitachycardia therapy, including 
pacing, cardioversion and defibrillation, to terminate in-
duced arrhythmias was then assessed and detection and 
therapy variables were programmed accordingly. 
FoUow-up. Patients were reviewed at I, 3, 6, 9 and 12 
months after implantation and after any clinical event. The 
device was interrogated to determine the therapy delivered, 
success rate and the RR intervals of the last event. Pacing 
threshold and R wave amplitude were determined and non-
invasive ventricular programmed stimulation studies per-
formed by the device. 
Analysis of tachycardia episodes. In the absence of docu-
mentation by Holter electrocardiographic (ECG) monitor-
ing, a tachycardia episode was classified as ventricular 
tachycardia if it was accompanied by typical clinical 
symptoms and the RR intervals of the recorded tachycardia 
were regular and consistent with previously documented 
ventricular tachycardia. Sinus tachycardia was diagnosed if 
the episode occurred during exercise, was unaccompanied 
by symptoms and if the recorded RR intervals were regular 
and consistent with sinus tachycardia. A tachycardia epi-
sode was classified as atrial fibrillation if it was unaccompa-
nied by symptoms of ventricular tachycardia and if 
the recorded RR intervals were irregular. Ventricular 
fibrillation was diagnosed if the tachycardia episode was 
symptomatic and the recorded RR intervals were very 
short and irregular (mean RR interval <250 ms). All other 
episodes of tachycardia were classified as having an 
uncertain mechanism. If a patient experienced multiple 
episodes of tachycardia between interrogations, only the 
last RR intervals of the recorded tachycardia were available 
for analysis. In the absence of documentation to the 
contrary, tachycardia episodes without RR interval 
records were classified as being the same as the last recorded 
event. 
The device did not register pacing-induced acceleration of 
ventricular tachycardia separately in memory. To estimate 
the frequency of pacing-induced ventricular tachycardia 
acceleration, all episodes of tachycardia categorized as high 
rate tachycardia by the device that occurred in patients who 
had received antitachycardia pacing in the same time period 
were assumed to represent acceleration. Episodes of accel-
eration that did not result in sufficient shortening of the 
tachycardia cycle length to be detected as high rate tachy-
cardia were thus not included in this estimate. 
Statistics. Patient survival was estimated by the Kaplan-
Meier method. Patients undergoing cardiac transplantation 
were censored at the time of transplantation. Continuous 
variables are expressed as mean values ± SD unless other-
wise stated. 
Table 2. Operative Details in the 46 Patients 
Concomitant operative procedure 
Coronary artery bypass grafting 
Mitral valve replacement 
Defibrillation threshold (J) 
Defibrillatory system 
3 epicardial patches 
2 epicardial patches 
3 transvenous electrodes 
2 transvenous leads and subcutaneous patch 
Model 7216 
Model 7217 
*Mean ± SO. 
Results 
No. of Patients 
6 
1 
10.1 ± 4.4* 
34 
2 
5 
4 
36 
10 
Immediate postoperative results. From June 1989 to June 
1990, 46 patients underwent implantation of the device. 
Clinical features and the results of electrophysiologic testing 
are shown in Table 1 and operative details in Table 2. At 
predischarge electrophysiologic testing, sustained mono-
morphic ventricular tachycardia was induced in 26 patients. 
Antitachycardia pacing was utilized for 36 ventricular tachy-
cardia episodes and was successful 32 times (89%). Accel-
eration to ventricular fibrillation occurred twice (6%) with 
subsequent successful defibrillation (Fig. 3) and the remain-
ing two tachycardia episodes (6%) were terminated by 
cardioversion therapy after failure of antitachycardia pacing. 
Sixteen ventricular tachycardia episodes were directly ter-
minated by cardioversion shocks because they were de-
tected as high rate tachycardia. Ventricular fibrillation was 
induced in 32 patients and was appropriately detected and 
defibrillated on all occasions. Details of device programming 
at hospital discharge are shown in Table 3. 
FoUow-up. Over a total follow-up period of 255 patient-
months (range 1 to 13), 25 patients (54%) experienced 953 
spontaneous arrhythmic events. In patients experiencing 
tachycardia episodes, the median number of episodes was 16 
(range 1 to 164). 
Tachycardias initiaUy treated by antitachycardia pacing. 
In 22 patients, 909 episodes of spontaneous tachycardia were 
initially treated by antitachycardia pacing, which success-
fully terminated the tachycardia on 840 occasions (92.4%) 
(Fig. 4). Ventricular tachycardia terminated by antitachycar-
dia pacing was documented by Holter ECG monitoring in 
eight patients (Fig. 2). Of the 909 episodes, 614 episodes in 
15 patients were classified clinically as ventricular tachycar-
dia and were treated successfully by pacing on 555 occasions 
(90%). Pacing-induced acceleration of ventricular tachycar-
dia was estimated to have occurred 39 times (4.3% of pacing 
episodes) in five of the patients receiving pacing therapy. 
Only one of the episodes of tachycardia acceleration was 
accompanied by syncope. 
Thirty-eight tachycardia episodes in six patients were 
classified clinically as sinus tachycardia. Detection of sinus 
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Table 3. Device Programming at Hospital Discharge in the 
46 Patients 
Tachycardia detection cycle length (ms) 
Low rate tachycardia detection 
High rate tachycardia detection 
High rate tachycardia detection ;?:270 ms 
First therapy for low rate tachycardia 
Decremental pacing 
Burst pacing 
Cardioversion (5 J) 
Not activated 
Second therapy for low rate tachycardia 
Decremental pacing 
Burst pacing 
Cardioversion (mean 8.7 ± 6.1 J) 
Not activated 
Third and fourth therapies for low rate tachycardia 
Cardioversion 
Not activated 
First therapy for high rate tachycardia 
High energy shock (mean 22 ± 9 J) 
Second to fourth therapies for high rate tachycardia 
(34 J shocks) 
*Mean ± SD. 
No. of Patients 
403 ± 34* 
290 ± 25* 
40 
38 
2 
2 
II 
30 
33 
3 
46 
46 
tachycardia with delivery of pacing therapy was documented 
in two of these patients during exercise stress testing. On 
one occasion, antitachycardia pacing delivered during sinus 
tachycardia initiated ventricular tachycardia (subsequently 
cardioverted by the device). The origin of the remaining 257 
episodes of tachycardia remained uncertain because they 
were asymptomatic or the stored data were inconclusive. 
Cardioversion was successful in 19 of the 30 tachycardia 
events that persisted despite antitachycardia pacing. The 11 
episodes unsuccessfully treated with shocks resolved spon-
taneously because the patients were in sinus rhythm when 
the device was interrogated. Each of the 11 episodes was 
classified clinically as sinus tachycardia according to the 
study criteria. These episodes of presumed sinus tachycardia 
had been treated inappropriately by pacing and then by 
shock therapy. Defibrillator shocks during sinus tachycardia 
were documented in two patients. All episodes classified 
clinically as ventricular tachycardia were successfully 
treated by cardioversion shocks. 
Tachycardias initially treated by shocks. A total of 44 high 
rate tachycardia episodes in seven patients were treated 
directly with high energy shocks; these were always success-
ful. Polymorphic ventricular tachycardia was documented 
on 29 occasions in one patient. Seven episodes in three 
patients were classified as rapid ventricular tachycardia. 
Two episodes in one patient were classified as primary 
ventricular fibrillation. Atrial fibrillation resulted in shock 
therapy on five occasions in one patient. In one patient in 
whom the high rate tachycardia detection interval had been 
programmed to 370 ms, sinus tachycardia was detected as 
high rate tachycardia and treated with a single countershock. 
Apart from the one patient who experienced syncope with 
acceleration of ventricular tachycardia, no other patient 
experienced syncope during either shock or pacing therapy. 
Antiarrhythmic medication. Antiarrhythmic medication 
was prescribed in 13 patients at hospital discharge. During 
follow-up, a further three patients were started on antiar-
rhythmic medication for control of frequent ventricular 
tachycardia resulting in device shocks. A beta-adrenergic 
blocking agent was given to five patients (three of whom 
were also taking other antiarrhythmic agents) to limit the 
maximal heart rate during sinus tachycardia. Antiarrhythmic 
medication was given to 15 of the 25 patients experiencing 
spontaneous tachycardia episodes. 
Mortality (Fig. 5). Of the five deaths in this study group, 
two were perioperative deaths unrelated to cardiac arrhyth-
mias (30 day hospital mortality rate 4.3%). One patient died 
suddenly 9 weeks after implantation of the device. Teleme-
try from the device after death revealed no detected tachy-
arrhythmias and consequently no delivered therapy. At 
attempted resuscitation 30 min after cardiac arrest, the 
patient was found to be asystolic with bradycardia pacing 
but no capture. At postmortem study, amiodarone lung 
toxicity and bilateral acute pneumonia were found. The 
953 tachy'cardia 
episodes 
Figure 4. Flow diagram of treatment of 953 
tachycardia episodes in this study. The device 
categorized tachycardia as either "low rate" or 
"high rate" on the basis of cycle length criteria. 
Low rate tachycardia episodes were all treated 
initially by antitachycardia pacing, whereas high 
rate tachycardia episodes were treated directly 
with shocks (see text and Fig. I for details). 840 successfully treated 
with pacing 
19 successfully treated 
with shocks 
11 shocks unsuccessful, 
terminated spontaneously 
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Figure 5. Kaplan-Meier plot of the probability of survival (solid line) 
and freedom from sudden death (dashed line) after implantation of 
the device in 46 patients. 
defibrillatory system was macroscopically intact. The other 
causes of death during long-term follow-up evaluation were 
respiratory failure in one patient and cardiac failure in 
another. All other patients are alive and have current follow-
up. The probability of survival to 6 months (including 
operative mortality) was 0.86 (SE 0.06) and the probability of 
freedom from sudden death to 6 months was 0.97 (SE 0.03). 
Device explanation. The device was explanted in two 
patients when cardiac transplantation was performed for 
refractory cardiac failure. 
Discussion 
Successful graded therapy for ventricular arrhythmias. 
Although the implantable defibrillator may prolong survival 
in patients with malignant ventricular arrhythmias (13,14), 
recurrent device shocks can result in substantial fear and 
anxiety (10,15). Frequent high energy shocks may lead to 
premature battery depletion and result in myocardial damage 
(16,17). A desired goal in the development of implantable 
antitachycardia devices has been graded therapy for ventric-
ular tachycardia. Ideally, a device capable of graded therapy 
would treat hemodynamically stable tachycardia with pacing 
therapy and reserve shock therapy for tachycardia that is 
unresponsive to pacing or hemodynamically unstable. In this 
study, only heart rate criteria were used to discriminate 
between the delivery of pacing and shock therapy. Never-
theless, the large majority of episodes of tachycardia were 
treated successfully by antitachycardia pacing. Only 12 of 
the 25 patients experiencing tachycardia episodes received 
defibrillator shocks and 840 tachycardia episodes (88% of all 
detected episodes) were treated successfully by pacing with-
out the need for countershocks. Because of differences in 
patient selection and length offollow-up, it is not possible to 
directly compare our study with other reports of defibrillator 
implantation. Nevertheless, it is clear that the use of a 
defibrillator committed to delivery of high energy shocks for 
any detected tachyarrhythmia would have resulted in a 
markedly increased number of shocks in our study patients. 
Pacing-induced acceleration of ventricular tachycardia. 
Attempted termination of ventricular tachycardia by pacing 
therapy has been shown (2-5) to result in ventricular tachy-
cardia acceleration or degeneration into ventricular fibrilla-
tion in 4% to 35% of tachycardia episodes. In this series, 
acceleration of ventricular tachycardia by pacing therapy 
appeared to be relatively infrequent, possibly because of the 
use of rate-adaptive antitachycardia pacing programmed to 
commence at cycle lengths close to the detected tachycardia 
cycle lengths (3). In addition, antitachycardia pacing was 
rarely chosen as therapy for episodes of tachycardia with a 
cycle length of ~260 ms because of the risk of hemodynamic 
instability during antitachycardia pacing. Excluding rapid 
tachycardia episodes from pacing therapy reduces the risk of 
tachycardia acceleration (4,5) but results in treatment of 
some ventricular tachycardias directly with shocks. Only 
one episode of syncope occurred during pacing therapy, 
confirming its safety as implemented in this study. Decre-
mental pacing was chosen as the primary form of antitachy-
cardia pacing in nearly all patients. Thus, no conclusions can 
be made about the relative efficacy and safety of decremental 
and burst pacing. 
Inappropriate therapy. A significant problem encoun-
tered was inappropriate therapy delivery during supraven-
tricular tachycardia-in particular, sinus tachycardia. In 
some patients, the cycle length of ventricular tachycardia 
overlapped with the maximal heart rate during exercise or 
atrial fibrillation. Additional tachycardia detection criteria, 
including cycle length stability, tachycardia onset criteria 
and hemodynamic variables, may allow better discrimina-
tion between supraventricular tachycardia and ventricular 
tachycardia (18,19). Although cycle length stability and 
tachycardia onset detection criteria were available with this 
device, they were not implemented because detection of 
supraventricular tachycardia did not recur after adjustment 
of antiarrhythmic medication and tachycardia detection in-
tervals. 
Eleven episodes of tachycardia were unsuccessfully 
treated with shocks. These shocks occurred during exercise 
and were not associated with symptoms of tachycardia. 
Because patients were often unable to recognize delivery of 
pacing therapy, it was possible for the device to cycle 
through several antitachycardia pacing sequences and then 
deliver shock therapy during prolonged exercise. These 
shocks were registered as unsuccessful, presumably because 
sinus tachycardia continued immediately after delivery of 
the shocks. Although it is not possible to exclude delayed or 
spontaneous termination of exercise-induced ventricular 
tachycardia, it is clear that these patients with unsuccessful 
shock therapy did not have hemodynamically unstable ven-
tricular tachycardia because they were asymptomatic before 
and after the shocks. 
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Antiarrhythmic medication. The intent was to maintain 
all patients free of antiarrhythmic medication after hospital 
discharge. This was not possible in 18 patients because of 
frequent ventricular arrhythmias or inappropriate detection 
of sinus tachycardia. In patients experiencing frequent 
tachycardia episodes, adjustment of antiarrhythmic medica-
tion was considered appropriate to minimize device shocks. 
The cause of death in the one patient who died suddenly 
remains undetermined. It is possible that this patient expe-
rienced ventricular fibrillation that was undetected by the 
device because of low electrogram amplitude. Alternatively, 
primary electromechanical dissociation may have been the 
mechanism of death (20). 
Limitations of the study. This device is only able to store 
the RR intervals of the last tachycardia event preceding 
interrogation. For this reason and because this device does 
not store analog data, the clinical diagnosis of some episodes 
of tachycardia may have been incorrect. In addition, 257 
tachycardia events could not be classified, usually because 
the patient could not recall any symptomatic episodes of 
tachycardia during the period in which the device had 
recorded and treated an event. Many of these episodes were 
probably asymptomatic ventricular tachycardia. The present 
device does not record the time a detected episode of 
tachycardia occurred; in future devices, implementation of 
this feature may help to diagnose asymptomatic or minimally 
symptomatic tachycardia episodes. Nevertheless, the mem-
ory facilities of the device did allow a more satisfactory 
analysis of detected tachycardia and delivered therapy than 
has previously been possible (7,8,13,21). 
Only limited follow-up data are available at present and 
these results need to be confirmed by further long-term 
studies. However, this initial experience suggests that a 
device that provides graded therapy with antitachycardia 
pacing of ventricular tachycardia and fibrillation is able to 
successfully treat the majority of tachycardia events without 
the need for high energy countershocks. 
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